166 related articles for article (PubMed ID: 23410950)
1. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
2. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
4. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
5. Renal effects of anti-angiogenesis therapy: update for the internist.
Gurevich F; Perazella MA
Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
[TBL] [Abstract][Full Text] [Related]
6. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
[TBL] [Abstract][Full Text] [Related]
8. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
[TBL] [Abstract][Full Text] [Related]
9. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
Ishak RS; Aad SA; Kyei A; Farhat FS
Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
[TBL] [Abstract][Full Text] [Related]
11. Proteinuria and VEGF-targeted therapies:
an underestimated toxicity?
Izzedine H; Soria JC; Escudier B
J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
[TBL] [Abstract][Full Text] [Related]
12. [Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors].
Rollino C; Beltrame G; Ferro M; Quattrocchio G; Tonda L; Quarello F
G Ital Nefrol; 2010; 27 Suppl 50():S70-4. PubMed ID: 20922699
[TBL] [Abstract][Full Text] [Related]
13. [Anticancer drugs under pressure].
Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
[TBL] [Abstract][Full Text] [Related]
15. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
Izzedine H
Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF molecular targeted therapies in common solid malignancies: comprehensive update for radiologists.
Tirumani SH; Fairchild A; Krajewski KM; Nishino M; Howard SA; Baheti AD; Rosenthal MH; Jagannathan JP; Shinagare AB; Ramaiya NH
Radiographics; 2015; 35(2):455-74. PubMed ID: 25763729
[TBL] [Abstract][Full Text] [Related]
17. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
19. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
Cosmai L; Gallieni M; Liguigli W; Porta C
J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
[TBL] [Abstract][Full Text] [Related]
20. Renal Toxicities of Targeted Therapies.
Abbas A; Mirza MM; Ganti AK; Tendulkar K
Target Oncol; 2015 Dec; 10(4):487-99. PubMed ID: 25922090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]